Date:2/23/2012

d provides unprecedented biological insight to address complex treatment decisions.  Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint­­, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 gene expression assay, and TheraPrint®, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.  Agendia is based in Irvine, California, U.S., and Amsterdam, the Netherlands.  For more information, please visit www.agendia.com.Contacts:

  

 Rubicon Genomics

MediaJames Koziarz

Barbara LindheimChief Executive Officer

 GendeLLindheim BioCom Partnersjkoziarz@rubicongenomics.com

(212) 584-2276 

blindheim@biocompartners.com

'/>"/>

SOURCE Rubicon Genomics, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. New England Biolabs and Rubicon Genomics Enter into Distribution Agreement for Single Cell Amplification Products
2. Sandell Asset Management Seeks Sale of Rubicon & Tenon, Expansion of Board
3. New Data Show Rubicons Unique Amplification Technology Enables Genetic And Epigenetic Analyses of Single Cells Using Next-Generation Sequencing
4. ZyGEM Corp. Signs Agreement to Incorporate Its Breakthrough DNA Extraction Technology Into Rubicons Research and Diagnostic Products
5. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
6. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
7. SwitchGear Genomics and New England Biolabs Develop New Multiplex Reporter Assay System
8. Synthetic Genomics Inc. and Plenus, S.A. de C.V. Form New Sustainable Agriculture Company, Agradis, Inc. to Develop and Commercialize Products Using Genomic Technologies
9. Center for Proteomics at the Translational Genomics Research Institute (TGen) Selected as Waters Center of Innovation
10. ACMG Announces New Online Live Learning Center: Will Bring Genetics and Genomics Education to Varied Health Professionals
11. Clinical Genomics Extends Strategic Alliance for Colorectal Cancer Testing Development with Quest Diagnostics